Internal Radiation Therapy Market Size, Growth and Forecast 2032

Market Overview:

Internal Radiation Therapy Market size was valued at USD 1115 million in 2024 and is anticipated to reach USD 1845.32 million by 2032, at a CAGR of 6.5% during the forecast period (2024-2032).

The primary growth drivers of the internal radiation therapy market include the rising incidence of cancer, particularly prostate, cervical, and breast cancers, where internal radiation therapy is widely used. Increasing awareness about minimally invasive treatment options and their efficacy in reducing side effects compared to external beam radiation therapy is also boosting market adoption. Technological advancements, such as high-dose rate (HDR) brachytherapy and image-guided techniques, are enhancing treatment precision, thereby improving patient outcomes. Additionally, supportive government policies, increasing healthcare expenditure, and growing investments in oncology research are further accelerating market growth. The integration of artificial intelligence (AI) in radiation therapy planning is also improving treatment accuracy and efficiency. Furthermore, the growing adoption of radionuclide therapy for metastatic cancer management is expanding the market scope.

North America dominates the internal radiation therapy market due to the high prevalence of cancer, advanced healthcare infrastructure, and significant R&D investments. The United States holds the largest market share, driven by technological innovations and increasing patient awareness. Europe follows closely, with strong government support for cancer treatment initiatives and an expanding elderly population. Meanwhile, the Asia-Pacific region is expected to witness the fastest growth, attributed to rising cancer cases, improving healthcare access, and growing medical tourism in countries like India and China. The increasing establishment of specialized cancer centers and collaborations between public and private healthcare providers are further strengthening regional growth. Additionally, rising government initiatives to enhance radiation therapy accessibility are expected to boost market expansion in emerging economies.

Market Insights:

• The internal radiation therapy market was valued at USD 1115 million in 2024 and is projected to reach USD 1845.32 million by 2032, growing at a CAGR of 6.5% during the forecast period.
• Increasing cases of prostate, cervical, and breast cancers are driving market demand, as internal radiation therapy provides effective, minimally invasive treatment with fewer side effects.
• Advancements such as high-dose rate (HDR) brachytherapy, image-guided radiation therapy (IGRT), and AI-driven treatment planning are improving treatment precision and efficiency.
• North America dominates the market with a 45.52% share, followed by Europe at 30.25%, while Asia-Pacific is the fastest-growing region, supported by healthcare advancements and increasing medical tourism.
• Supportive government policies, increased oncology research funding, and favorable reimbursement structures are accelerating market expansion across various regions.
• High treatment costs, limited accessibility in developing regions, and a shortage of skilled radiation oncologists are significant challenges restricting widespread adoption.
• The market is expected to expand further due to rising adoption of radionuclide therapy for metastatic cancers, increasing demand for outpatient treatments, and growing investments in healthcare infrastructure worldwide.

Market Drivers:

Rising Cancer Prevalence and Expanding Patient Base

The increasing global burden of cancer is a primary driver for the internal radiation therapy market. With the rising incidence of prostate, cervical, and breast cancers, internal radiation therapy, particularly brachytherapy and targeted radionuclide therapies, is becoming an essential treatment modality. For instance, the American Cancer Society estimates over 2 million new cancer cases will be diagnosed in the US in 2025. According to leading cancer research organizations, cancer cases are expected to grow significantly in the coming decades, primarily due to aging populations and lifestyle-related risk factors. This surge in cancer prevalence is driving the demand for effective and minimally invasive treatments, positioning internal radiation therapy as a crucial solution.

Technological Advancements in Radiation Therapy

Continuous innovations in radiation therapy technologies are enhancing treatment accuracy, efficiency, and patient outcomes. The introduction of high-dose rate (HDR) brachytherapy, real-time image-guided radiation therapy (IGRT), and artificial intelligence (AI)-driven radiation planning systems has significantly improved precision in radiation delivery. For instance, UI Health Care is the first medical center in North America to advance MR-Linac technology, offering more precise real-time targeting of soft tissue tumors with radiation therapy. These advancements minimize damage to surrounding healthy tissues, thereby reducing side effects and improving patient recovery times. Additionally, the development of new radioisotopes and targeted radionuclide therapies, such as Lutetium-177 and Actinium-225, is expanding the scope of internal radiation treatments, further accelerating market growth.

Government Support and Increasing Healthcare Expenditure

Supportive government policies and increasing healthcare spending are fueling the adoption of internal radiation therapy. Governments across North America, Europe, and Asia-Pacific are investing in cancer treatment infrastructure, launching awareness programs, and approving new radiation therapy techniques to improve accessibility. For instance, the Indian government plans to establish day-care cancer centers in all district hospitals, with 200 centers to be established in 2025-26. Public and private investments in oncology research and radiation therapy centers are further strengthening market expansion. Additionally, the presence of favorable reimbursement policies for radiation therapy in developed economies is reducing financial barriers for patients, contributing to the widespread adoption of internal radiation treatments.

Growing Preference for Minimally Invasive and Targeted Therapies

The demand for minimally invasive cancer treatments is growing, as patients and healthcare providers seek therapies that offer higher precision with fewer complications. Internal radiation therapy provides targeted treatment, reducing radiation exposure to healthy tissues compared to external beam radiation therapy (EBRT). This advantage is driving its preference among oncologists and patients alike. For instance, the NHS has launched a trial for a cancer vaccine. Moreover, the increasing use of combination therapies, integrating internal radiation therapy with chemotherapy or immunotherapy, is further enhancing its effectiveness in cancer management. As awareness about these benefits grows, the market is expected to witness continued expansion.

Market Trends:

Advancements in Image-Guided and AI-Driven Radiation Therapy

The internal radiation therapy market is witnessing significant advancements in image-guided radiation therapy (IGRT) and artificial intelligence (AI)-driven treatment planning. For instance, GE HealthCare is enhancing its PET/MR capabilities with AIR technologies to increase diagnostic precision and simplify treatment evaluations, which also improves patient comfort during scans. These technologies are improving the precision and accuracy of radiation dose delivery, minimizing damage to surrounding healthy tissues. AI is also being integrated into radiation oncology to enhance treatment personalization, optimize dose distribution, and reduce procedural time, leading to better patient outcomes.

Rising Adoption of Targeted Radionuclide Therapy

Targeted radionuclide therapy is gaining momentum as a promising approach in cancer treatment. The increasing use of radioisotopes such as Lutetium-177 and Actinium-225 in treating metastatic cancers is expanding the scope of internal radiation therapy. For instance, the FDA approved Lutetium-177 PSMA therapy for use in 2022, which improves progression-free and overall survival in men with metastatic castration-resistant prostate cancer. These treatments are particularly effective in addressing prostate cancer and neuroendocrine tumors, driving their adoption among healthcare providers. The development of novel radiopharmaceuticals is expected to further enhance market growth.

Growing Preference for Outpatient and Ambulatory Care Settings

With the shift towards minimally invasive treatments, internal radiation therapy is increasingly being administered in outpatient and ambulatory care settings. High-dose rate (HDR) brachytherapy allows for shorter treatment durations, reducing hospital stays and improving patient convenience. For instance, Fortis Healthcare is adopting new-age treatments for home-care and remote monitoring and optimizing patient stays to reduce costs. This trend is driven by cost-effectiveness, improved accessibility, and enhanced patient comfort, making internal radiation therapy an attractive option in modern oncology care.

Expansion of Cancer Treatment Infrastructure in Emerging Markets

Emerging economies, particularly in Asia-Pacific and Latin America, are witnessing rapid expansion in cancer treatment facilities and radiation therapy accessibility.  For instance, India is expanding access to specialized cancer treatment centers under the "Strengthening of Tertiary Care Cancer Centres" program. Governments and private organizations are investing in oncology centers, medical tourism, and healthcare workforce training to improve cancer care. This trend is contributing to the growing adoption of internal radiation therapy in regions with historically limited access to advanced cancer treatments.

Market Challenges Analysis:

High Treatment Costs and Limited Accessibility

One of the significant challenges in the internal radiation therapy market is the high cost of treatment and limited accessibility in developing regions. Advanced radiation therapy techniques, such as high-dose rate (HDR) brachytherapy and targeted radionuclide therapy, require sophisticated equipment, skilled professionals, and specialized healthcare facilities. These factors contribute to high operational costs, making treatment expensive for patients, especially in low- and middle-income countries. Additionally, the availability of internal radiation therapy is often restricted to urban healthcare centers, limiting access for patients in rural and underserved regions. The lack of sufficient reimbursement policies in several countries further exacerbates affordability issues, hindering the widespread adoption of these therapies.

Shortage of Skilled Radiation Oncologists and Regulatory Hurdles

The shortage of trained radiation oncologists and medical physicists poses a critical barrier to the expansion of internal radiation therapy. The complexity of treatment planning and delivery demands highly skilled professionals, but a global workforce shortage is slowing adoption rates, particularly in emerging markets. Furthermore, stringent regulatory requirements for the approval and safe handling of radioactive materials present additional challenges for market growth. Compliance with radiation safety protocols, licensing requirements, and strict government regulations increases the time and cost required for market entry, delaying the introduction of new technologies. Addressing these challenges through investments in medical training programs and streamlined regulatory frameworks will be crucial for sustaining market growth.

Market Opportunities:

The internal radiation therapy market presents significant opportunities driven by the increasing demand for personalized cancer treatments and advancements in radiopharmaceuticals. The development of novel targeted radionuclide therapies, such as Lutetium-177 and Actinium-225-based treatments, is expanding the scope of internal radiation therapy for various cancers, including prostate and neuroendocrine tumors. These innovations offer higher treatment precision with fewer side effects, making them an attractive alternative to conventional therapies. Additionally, the integration of artificial intelligence (AI) and real-time imaging techniques in radiation therapy planning is enhancing treatment accuracy and efficiency, improving patient outcomes. The rising focus on combination therapies, where internal radiation therapy is used alongside immunotherapy and chemotherapy, is further increasing its clinical applications and market potential.

Expanding healthcare infrastructure in emerging economies is also creating new growth avenues for internal radiation therapy. Countries in Asia-Pacific, Latin America, and the Middle East are investing heavily in oncology centers, radiation therapy training programs, and medical tourism, improving access to advanced cancer treatments. Governments and private organizations are also launching initiatives to enhance radiation therapy affordability through subsidies and reimbursement policies, encouraging wider adoption. The shift towards outpatient and ambulatory care settings, driven by high-dose rate (HDR) brachytherapy and minimally invasive procedures, is reducing treatment costs and increasing patient convenience. As awareness and accessibility improve, the market is expected to witness sustained growth, particularly in regions where internal radiation therapy adoption has historically been limited.

Market Segmentation Analysis:

By Product Type

The internal radiation therapy market is segmented into brachytherapy and targeted radionuclide therapy. Brachytherapy, which includes low-dose rate (LDR) and high-dose rate (HDR) brachytherapy, remains a widely utilized treatment for localized cancers such as prostate, cervical, and breast cancer. LDR brachytherapy is commonly used in permanent implants, while HDR brachytherapy offers flexibility with controlled radiation dosing. Targeted radionuclide therapy, using radioisotopes like Lutetium-177 and Actinium-225, is witnessing growing adoption, particularly for metastatic cancers and neuroendocrine tumors, as it enables precise targeting of cancerous cells with minimal impact on healthy tissues.

By Dosage Type

Internal radiation therapy is categorized into low-dose rate (LDR) and high-dose rate (HDR) therapies. LDR therapy is typically used for permanent radioactive seed implants, particularly in prostate cancer treatment, ensuring a continuous, localized radiation dose over time. HDR therapy, in contrast, is favored for its shorter treatment cycles and ability to be administered in outpatient settings, reducing hospital stays while maintaining treatment efficacy. The increasing preference for minimally invasive treatment approaches is driving the adoption of HDR brachytherapy in modern oncology care.

By Application

The primary applications of internal radiation therapy include prostate, cervical, breast, and other cancers. Prostate cancer holds a major market share due to the effectiveness of brachytherapy in localized treatment. Additionally, the rising incidence of gynecological and breast cancers is driving demand for brachytherapy and targeted radionuclide therapy. The increasing adoption of radiopharmaceuticals for neuroendocrine tumors and metastatic cancers is further expanding the market scope, highlighting its potential in a broader range of clinical applications.

Segmentations:

By Product Type:

• • Brachytherapy (Low-Dose Rate, High-Dose Rate)
  • Targeted Radionuclide Therapy (Lutetium-177, Actinium-225)

By Dosage Type:

• • Low-Dose Rate (LDR)
  • High-Dose Rate (HDR)

By Application:

• • Prostate Cancer
  • Cervical Cancer
  • Breast Cancer
  • Neuroendocrine Tumors
  • Metastatic Cancers

By Region:

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • France
  • U.K.
  • Italy
  • Spain
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • South-east Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Argentina
  • Rest of Latin America
• Middle East & Africa
  • GCC Countries
  • South Africa
  • Rest of the Middle East and Africa

Regional Analysis:

North America

North America leads the internal radiation therapy market, accounting for 45.52% of the global revenue share. This dominance is attributed to a well-established healthcare infrastructure, a strong presence of industry players, and high adoption of advanced treatment devices in hospitals and cancer care centers. The United States holds a significant portion of the market, driven by increasing investments in oncology research and the availability of cutting-edge radiation therapy technologies. Moreover, favorable reimbursement policies for diagnostic imaging and cancer treatment procedures further support market expansion. The presence of well-funded healthcare institutions and collaborations between public and private entities is accelerating innovation and market growth.

Europe

Europe holds a significant share of the internal radiation therapy market, contributing to 30.25% of global revenue. The region benefits from strong government support for cancer treatment initiatives, extensive medical research, and an aging population with higher cancer prevalence. The adoption of high-dose rate (HDR) brachytherapy and targeted radionuclide therapies is increasing, enhancing treatment precision and patient outcomes. Regulatory policies in European countries promote the integration of advanced radiation therapy solutions, while collaborations between research institutions and healthcare providers are fostering market expansion. Countries such as Germany, France, and the UK are leading the region’s growth due to their extensive oncology research, well-developed healthcare infrastructure, and favorable reimbursement structures.

Asia-Pacific

The Asia-Pacific region is experiencing rapid growth, accounting for 18.63% of the global market share and is expected to expand further due to rising cancer prevalence, improving healthcare access, and increasing government investments in radiation therapy facilities. Countries like China, India, Japan, and South Korea are witnessing rapid economic development, leading to greater accessibility to advanced cancer treatment technologies. Additionally, rising healthcare expenditure, growing public awareness about radiotherapy options, and an increasing geriatric population are fueling market demand. The region is also seeing a surge in medical tourism, particularly for cost-effective and advanced cancer treatments, further propelling growth. Expanding oncology training programs and government initiatives to enhance radiation therapy infrastructure are strengthening the market outlook.

Key Player Analysis:

• IsoRay Medical Inc.
• Eckert & ZieglerVarian Medical Systems Inc.
• Theragenics Corporation
• Elekta AB
• Becton, Dickinson and Company
• Varian Medical Systems
• Accuray Incorporated
• CIVCO Medical Solutions
• Sun Nuclear Corporation
• ICAD Inc.

Competitive Analysis:

The internal radiation therapy market is highly competitive, with key players focusing on technological advancements, strategic partnerships, and product innovations to strengthen their market presence. Eckert & Ziegler specializes in radioisotope-based cancer treatments and is expanding its product portfolio to enhance therapeutic precision. Varian Medical Systems Inc., a leader in radiation oncology, continues to innovate in brachytherapy and targeted radionuclide therapy, leveraging cutting-edge technology to improve patient outcomes. For instance, AI and machine learning algorithms can optimize brachytherapy plans based on patient-specific data, maximizing therapeutic advantages while minimizing side effects.

IsoRay Medical Inc. is known for its Cesium-131 brachytherapy seeds, offering effective radiation solutions for localized cancers. Elekta AB focuses on high-dose rate (HDR) brachytherapy systems, expanding its footprint through strategic acquisitions and R&D investments. Theragenics Corporation specializes in low-dose rate (LDR) brachytherapy for prostate cancer treatment, strengthening its position with continuous product development. These companies compete on innovation, regulatory approvals, and global expansion strategies to maintain a competitive edge.

Recent Developments:

1. In May 2024 Physicians can now obtain Cesium-131 seeds for brachytherapy, an internal radiation, by the partnership between Theragenics Corporation and GT Medical Technologies.
2. In September 2024 Theragenics Corporation expanded its services to include contract manufacturing for the radiopharmaceutical industry. This move leverages Theragenics’ infrastructure and experience in radioisotope production to support the growing demand for innovative diagnostic and therapeutic radiopharmaceuticals.
3. In September 2024 Varian showcased its Ethos adaptive radiotherapy system, updated with new software features, at the 2024 American Society for Radiation Oncology (ASTRO) annual meeting.
4. In October 2024 BD (Becton, Dickinson and Company) launched the new BD® Intraosseous Vascular Access System, which enables quick access to the circulatory system for rapid delivery of fluids or medication in critical emergency situations.

Market Concentration & Characteristics:

The internal radiation therapy market is moderately concentrated, with a few key players holding a significant share due to technological expertise, strong R&D investments, and established global distribution networks. Companies such as Eckert & Ziegler, Varian Medical Systems Inc., IsoRay Medical Inc., and Elekta AB dominate the market by offering advanced brachytherapy and targeted radionuclide therapy solutions. These players focus on product innovation, regulatory approvals, and strategic collaborations to enhance their competitive positioning. The market is characterized by continuous technological advancements, increasing adoption of AI-driven treatment planning, and a growing demand for minimally invasive cancer therapies. Additionally, rising government support, favorable reimbursement policies, and expanding healthcare infrastructure in emerging economies are further shaping the market landscape. With increasing competition, companies are prioritizing portfolio expansion, mergers, and geographic expansion strategies to strengthen their market presence and cater to the rising demand for precision-based internal radiation treatments.

Report Coverage:

The research report offers an in-depth analysis based on Product Type, Dosage, Application and Region. It details leading market players, providing an overview of their business, product offerings, investments, revenue streams, and key applications. Additionally, the report includes insights into the competitive environment, SWOT analysis, current market trends, as well as the primary drivers and constraints. Furthermore, it discusses various factors that have driven market expansion in recent years. The report also explores market dynamics, regulatory scenarios, and technological advancements that are shaping the industry. It assesses the impact of external factors and global economic changes on market growth. Lastly, it provides strategic recommendations for new entrants and established companies to navigate the complexities of the market.

Future Outlook:

1. Advancements in radiopharmaceuticals will drive the adoption of targeted radionuclide therapy, improving treatment precision for various cancers.
2. Integration of artificial intelligence (AI) and machine learning in radiation therapy planning will enhance treatment accuracy and efficiency.
3. Rising demand for minimally invasive cancer treatments will accelerate the adoption of high-dose rate (HDR) brachytherapy and targeted therapies.
4. Expanding healthcare infrastructure in emerging economies will improve access to advanced radiation therapy solutions.
5. Increasing use of combination therapies will enhance treatment effectiveness, integrating internal radiation therapy with chemotherapy and immunotherapy.
6. Regulatory support and favorable reimbursement policies will encourage wider adoption and market expansion.
7. Development of novel isotopes and radiopharmaceuticals will provide more effective treatment options for metastatic and rare cancers.
8. Growth in outpatient and ambulatory care settings will support faster recovery and cost-effective cancer treatment solutions.
9. Strategic collaborations and mergers among key players will drive technological innovations and market competitiveness.
10. Ongoing clinical research and government initiatives will further enhance internal radiation therapy applications and improve patient outcomes.